TACSTD2
Tumor-associated calcium signal transducer 2
As of the edition of 20 October 2026, TACSTD2 (tumor-associated calcium signal transducer 2, UniProt P09758) has 16 drugs tested at it and 20 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P09758
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Cancer; Skin and connective tissue; Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Digestive system; Hormones; Nervous system
- Registered trials of its drugs
- 303
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 11 |
| Stopped | 2 |
| Total | 16 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sacituzumab govitecan | Marketed | Phase 4 | Ends 2032 |
| Sacituzumab tirumotecan | Active | Phase 3 | none listed |
| Datopotamab deruxtecan | Marketed | Phase 4 | Ends 2037 |
| JSKN016 | Active | Phase 3 | none listed |
| ESG401 | Active | Phase 3 | none listed |
| Sacituzumab | Marketed | Phase 2 | none listed |
| AVZO-103 | Active | Phase 2 | none listed |
| BAT8003 | Stopped | Phase 1 | none listed |
| DM001 | Active | Phase 1 | none listed |
| HS-20105 | Active | Phase 2 | none listed |
| LCB84 | Active | Phase 2 | none listed |
| MDX2001 | Active | Phase 2 | none listed |
12 of 16 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Engaged | 16 |
| Total on the list | 20 |
| Company | Route |
|---|---|
| Daiichi Sankyo | Route B |
| Gilead Sciences | Route B |
| Pfizer | Route A |
The other 17 companies at TACSTD2
In the product20 companies in all; 17 are not named here, and no score is.
See the 20 companies at TACSTD2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.